KT-Biologics I (KTB1): A dynamic simulation model for continuous biologics manufacturing

7Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The pharmaceutical industry's shift towards biological therapeutics has led to a transition from conventional batch production to continuous manufacturing. This change highlights the crucial need for effective process monitoring and control strategies to ensure consistent product quality and stability. Open-source benchmark simulation models have become essential tools for refining these processes, offering a platform for testing research hypotheses. This study uses the production of Lovastatin as a case study for continuous biopharmaceutical production. A comprehensive dynamic model covering upstream and downstream components provides an integrated perspective of the production process. The study introduces a basic control system emphasizing realistic sensor and actuator integration to enhance simulation accuracy. It assesses the benchmark through open-loop and closed-loop simulations, offering an in-depth analysis of the KTB1 model's dynamic response and functionality. KTB1 represents a model-driven decision support tool that enables the evaluation of monitoring strategies, process design, process optimization, and control for biomanufacturing.

Cite

CITATION STYLE

APA

Boskabadi, M. R., Ramin, P., Kager, J., Sin, G., & Mansouri, S. S. (2024). KT-Biologics I (KTB1): A dynamic simulation model for continuous biologics manufacturing. Computers and Chemical Engineering, 188. https://doi.org/10.1016/j.compchemeng.2024.108770

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free